Cloud Pharmaceuticals have entered into drug discovery collaboration with GlaxoSmithKline (GSK). Cloud will design novel small-molecule agents to GSK specified targets. Cloud will use its proprietary AI-driven process to design the molecules.
“Application of Cloud Pharmaceuticals technology has been proven to dramatically shorten the time from target validation to lead molecule. We believe this agreement validates the strength of this process and reinforces the value we can offer accelerate the discovery of novel, high-quality drug candidates,” Ed Addison, CEO of Cloud Pharmaceuticals, said.
Cloud Pharmaceuticals has designed active molecules with academic and commercial partners against a broad variety of drug targets and has published several papers to document its success. Cloud’s proprietary AI-driven process delivers completely novel molecules that have been tailored to the unique characteristics of each drug target.